Company Overview and News
ALLIANCE Mineral Assets on Friday said the company it has proposed to merge with, Tawana Resources NL, has secured a A$20 million (S$19.7 million) secured debt facility, as well as a conditional A$20 million standby line of credit, to facilitate the merged entity's admission to the Australian Securities Exchange (ASX).
40F SPXCY TAW SPXCF TWNAF S68
Tawana Resources NL (ASX:TAW) managing director Mark Calderwood speaks to Proactive Investors in detail about the ongoing merger process with Bald Hill Mine co-owner Alliance Mineral Assets (SGX:AMAL).
40F TAW TWNAF
Tawana Resources NL (ASX:TAW) (FRA:TJR) (JSE:TAW) has added 20% on its return to the bourse after securing a $40 million funding package from a Tribeca Investment Partners-led consortium.
40F TAW TWNAF AVZ
Lithium producer Tawana Resources has secured a $40 million funding package with a consortium led by Tribeca Investment Partners, with its planned merger with joint venture partner Alliance Mineral Assets expected to be completed in November.
40F TAW TWNAF
Tawana Resources has secured crucial funding that is expected to cement its future as an Australian-listed company following a proposed merger with Singapore’s Alliance Mineral Assets.
40F TAW TWNAF
Lithium market news - The Benchmark Minerals megafactory tracker is now at 41 in the pipeline.
LIT BCN PILBF LTHHF CXO SAV LAXXF LIACF AGY NMT PLLLY RDRUY AZZVF MS WML SQM MLNLF AIS.H KDR SYA STLHF WMLLF LNRDY NGZ AMVMF LMMFF GXY TAW LRS MNIKF ILHMF AMLM ALB DMNXF MALRY BGS LACDF EEYMF MIN NMKEF ARYMF ILC GALXF MGXMF LSSCF ALTAF DJIFF NMX EMH PSC CRECF OROCF ERPNF LAC PLS BCN TWNAF DJI RRSSF PDDTF NTTHF TSLA MALRF ORE AVZ AJM BCRMF
Joint venture partners Tawana Resources and Alliance Mineral Assets have achieved commercial production at the Bald Hill lithium mine in the Eastern Goldfields, Western Australia.
40F TAW EGS EGDD TWNAF ESGFF
Lithium market - Goldman: Concerns about a wave of supply of the electric car battery material from new mines are unfounded. The selloff in companies tied to lithium is overdone.
LIT BCN PILBF LTHHF CXO SAV LAXXF LIACF AGY NMT KSN PLLLY RDRUY AZZVF WML MLNLF AIS.H KDR DFS SYA STLHF WMLLF LNRDY NGZ LMMFF GXY TAW LRS MNIKF ILHMF AMLM DMNXF MALRY BGS LACDF EEYMF MIN NMKEF ARYMF ILC GALXF MGXMF LSSCF ALTAF DJIFF NMX EMH PSC CRECF OROCF ERPNF LAC PLS FTI.WI FMC BCN TWNAF DJI RRSSF PDDTF NTTHF AVLIF MALRF ORE AVZ AJM BCRMF
2018-06-25 seekingalpha - 1
Lithium market news - Simon Moores: We’re in the midst of a global battery arms race, now above 40 gigafactories.
LIT BCN PILBF LTHHF SAV LAXXF LIACF AGY NMT 40F PLLLY RDRUY AZZVF MS WML SQM MLNLF AIS.H KDR SYA STLHF WMLLF LNRDY NGZ AMVMF LMMFF GXY TAW LRS MNIKF ILHMF AMLM ALB DMNXF MALRY BGS LACDF EEYMF MIN NMKEF ARYMF ILC GALXF MGXMF LSSCF ALTAF DJIFF NMX EMH PSC CRECF OROCF ERPNF LAC PLS BCN TWNAF DJI RRSSF PDDTF NTTHF AVLIF NTR TSLA MALRF ORE AVZ AJM BCRMF
Electric vehicles have a long road ahead of them, even if Tesla sees a few twists and turns along the way.
PILBF SSNLF CCZ RNSDF HAV GALXF ALTAF GM VLKAY PLS AYR BC94 SMSN BSWQY DDAIF TWNAF KATFF GXY KAT TAW GOOGL MU AJM SMSD
Markets are taking a chance to settle down after a rocky week last week. Sentiment continues to be cautious. These are some of the small and mid-cap stories from Wednesday on the JSE:
KIBO TAW TWNAF
2018-05-27 seekingalpha - 1
Lithium spot and contract price news - Spot prices very slightly down and contract prices rising.
LIT BCN PILBF LTHHF SAV LAXXF LIACF AGY NMT 40F PLLLY RDRUY AZZVF WML SQM MLNLF AIS.H KDR SYA STLHF WMLLF LNRDY NGZ AMVMF VLKAF LMMFF GXY TAW LRS MNIKF ILHMF AMLM ALB DMNXF MALRY BGS LACDF EEYMF MIN NMKEF ARYMF ILC MGXMF LSSCF ALTAF DJIFF NMX EMH PSC CRECF OROCF ERPNF LAC PLS FTI.WI FMC BCN TWNAF DJI RRSSF PDDTF NTTHF AVLIF NTR MALRF ORE AVZ AJM BCRMF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ASX:TAW / TAWANA RESOURCES NL on message board site Silicon Investor.